# Medicure Inc. Medicure is a value-based pharmaceutical company committed to the development and commercializing of cardiovascular therapeutics. ## Additional Information - [About](https://www.medicure.com/about) - [Leadership](https://www.medicure.com/leadership) - [Board of Directors](https://www.medicure.com/board-of-directors) - [Our History](https://www.medicure.com/our-history) - [Mission and Values](https://www.medicure.com/mission-and-values) - [Medicure Marks Its 25th Anniversary](https://www.medicure.com/medicure-marks-its-25th-anniversary) - [People and Culture](https://www.medicure.com/people-and-culture) - [Careers](https://www.medicure.com/careers) - [Corporate Compliance](https://www.medicure.com/corporate-compliance) - [State Compliance](https://www.medicure.com/state-compliance) - [It Takes Guts to Find a Cure](https://www.medicure.com/perspectives/it-takes-guts-to-find-a-cure) - [Infusing Passion into My Desk Job](https://www.medicure.com/perspectives/infusing-passion-into-my-desk-job) - [Meet our VP of Medical and Business Affairs](https://www.medicure.com/meet-our-vp-of-medical-and-business-affairs) - [Meet our Compliance Officer](https://www.medicure.com/meet-our-compliance-officer) - [Christmas Cheer Board: A Community of Sharing and Giving](https://www.medicure.com/corporate-giving/christmas-cheer-board-a-community-of-sharing-and-giving) - [MEDA: Creating Sustainable Business Solutions to Poverty](https://www.medicure.com/corporate-giving/meda-creating-sustainable-business-solutions-to-poverty) - [Willow Place](https://www.medicure.com/willow-place) - [Indigenous Education Award](https://www.medicure.com/indigenous-education-award) - [Habitat For Humanity](https://www.medicure.com/habitat-for-humanity) - [Fort Garry Women's Resource Centre](https://www.medicure.com/fort-garry-womenand-x2019-s-resource-centre) - [25th Anniversary Interview with CEO Albert Friesen](https://www.medicure.com/interview-with-ceo-albert-friesen) - [MC-1 for PNPO Deficiency](https://www.medicure.com/p5p-for-pnpo-deficiency) - [About PNPO](https://www.medicure.com/about-pnpo) - [Products](https://www.medicure.com/products) - [AGGRASTAT® (tirofiban HCl) injection](https://www.medicure.com/aggrastat) - [Online Pharmacy](https://www.medicure.com/marley-drug) - [Sodium Nitroprusside Injection](https://www.medicure.com/sodium-nitroprusside-injection) - [Pipeline](https://www.medicure.com/pipeline) - [Drug Safety](https://www.medicure.com/drug-safety) - [Medical Information](https://www.medicure.com/medical-information) - [Patient Information](https://www.medicure.com/patient-information) - [Tardive Dyskinesia](https://www.medicure.com/tardive-dyskinesia) - [Business Development](https://www.medicure.com/business-development) - [Aggrastat Patents](https://www.medicure.com/aggrastat/patents) - [Zypitamag Patents](https://www.medicure.com/zypitamag/patents) - [About Marley Drug](https://www.medicure.com/marley-drug/about) - [Why Marley Drug](https://www.medicure.com/marley-drug/why-marley-drug) - [What We Offer](https://www.medicure.com/marley-drug/what-we-offer) - [Newsroom](https://www.medicure.com/news-and-media) - [News](https://www.medicure.com/news-and-media) - [Press Releases](https://www.medicure.com/press-releases) - [Social Media](https://www.medicure.com/social-media) - [Media](https://www.medicure.com/media) - [Dr Friesen SME](https://www.medicure.com/dr-friesen-sme) - [Monica Amin SME](https://www.medicure.com/monica-amin-sme) - [Leanne Taylor and the Road to Paris 2024](https://www.medicure.com/leanne-taylor-road-to-paris-) - [Why Medicure Aquired Marley Drug](https://www.medicure.com/why-medicure-aquired-marley-drug) - [Medicure Top 10](https://www.medicure.com/medicure-top-10) - [Marley Drug Top 10](https://www.medicure.com/marley-drug-top-10) - [Innovations](https://www.medicure.com/innovations) - [Marley Drug Acquisition](https://www.medicure.com/marley-drug-acquisition) - [Leanne Top 25](https://www.medicure.com/leanne-top-25) - [Albert Friesen BAM Leadership Award](https://www.medicure.com/albert-friesen-bam-leadership-award) - [Vanessa DSN Award](https://www.medicure.com/vanessa-dsn-award) - [Reuben Pharmacy Award](https://www.medicure.com/reuben-pharmacy-award) - [Best Place To Work Award](https://www.medicure.com/best-place-to-work-award) - [Celebrating Rare Disease Day](https://www.medicure.com/rare-disease-day) - [Investors](https://www.medicure.com/investors) - [Events](https://www.medicure.com/events) - [Presentations / Conference Calls](https://www.medicure.com/presentations-conference-calls) - [Stock Information](https://www.medicure.com/stock-information) - [Annual Reports](https://www.medicure.com/annual-reports) - [Quarterly Reports](https://www.medicure.com/quarterly-reports) - [Corporate Governance](https://www.medicure.com/corporate-governance) - [Investor Contacts](https://www.medicure.com/investor-contacts) - [Contact Us](https://www.medicure.com/contact-us) - [MedicureDirect](https://www.medicure.com/medicure-direct) - [Product Issues](https://www.medicure.com/medicure-direct/product-issues) - [Terms and Conditions](https://www.medicure.com/medicure-direct/terms-and-conditions) - [FABOLUS PRO](https://www.medicure.com/studies/fabpro2012) - [Moroi et al](https://www.medicure.com/studies/moroi2020) - [REAL-CAD](https://www.medicure.com/studies/realcad2018) - [FABFAST](https://www.medicure.com/studies/fabfast2020) - [COVID-19 Response](https://www.medicure.com/covid-19-response) - [Privacy Statement](https://www.medicure.com/wcm-docs/freetext/medicure_privacy_policy_20211026143327.pdf) - [Medicure International and Iroko Cardio Sign an Agreement for the Advancement of AGGRASTAT® Worldwide](https://www.medicure.com/press-releases/medicure-international-and-iroko-cardio-sign-an-agreement-for-the-advancement-of-aggrastat-worldwide) - [Medicure Announces Executive Officer Change](https://www.medicure.com/press-releases/medicure-announces-executive-officer-change) - [Medicure Announces Grant of Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-options-6) - [Medicure Announces Birmingham Debt Settlement](https://www.medicure.com/press-releases/medicure-announces-birmingham-debt-settlement) - [Medicure Announces Appointment of Dawson Reimer as President and Chief Operating Officer](https://www.medicure.com/press-releases/medicure-announces-appointment-of-dawson-reimer-as-president-and-chief-operating-officer) - [Medicure Announces Appointment of New CFO](https://www.medicure.com/press-releases/medicure-announces-appointment-of-new-cfo) - [Medicure Reports Financial Results for Fiscal 2011](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-fiscal-2011) - [Medicure Announces Graduation to TSX Venture Exchange](https://www.medicure.com/press-releases/medicure-announces-graduation-to-tsx-venture-exchange) - [Medicure Reports First Quarter 2012 Financial Results](https://www.medicure.com/press-releases/medicure-reports-first-quarter-2012-financial-results) - [Medicure Provides Update on TEND-TD Phase II Clinical Trial](https://www.medicure.com/press-releases/medicure-provides-update-on-tend-td-phase-ii-clinical-trial) - [Medicure Reports Second Quarter 2012 Financial Results](https://www.medicure.com/press-releases/medicure-reports-second-quarter-2012-financial-results) - [Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI](https://www.medicure.com/press-releases/medicure-announces-aggrastat-clinical-trial-savi-pci) - [Medicure Reports Third Quarter 2012 Financial Results](https://www.medicure.com/press-releases/medicure-reports-third-quarter-2012-financial-results) - [Medicure Announces Commencement of Enrollment in SAVI-PCI Trial of AGGRASTAT](https://www.medicure.com/press-releases/medicure-announces-commencement-of-enrollment-in-savi-pci-trial-of-aggrastat) - [Medicure Reports Financial Results for Fiscal 2012](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-fiscal-2012) - [Medicure Announces Proposed Fifteen to One Share Consolidation](https://www.medicure.com/press-releases/medicure-announces-proposed-fifteen-to-one-share-consolidation) - [Medicure Announces Development of Novel AGGRASTAT Formulation](https://www.medicure.com/press-releases/medicure-announces-development-of-novel-aggrastat-formulation) - [Medicure Announces Intention to Seek Expanded Aggrastat Label](https://www.medicure.com/press-releases/medicure-announces-intention-to-seek-expanded-aggrastat-label) - [Medicure Reports First Quarter Financial Results for Fiscal 2013](https://www.medicure.com/press-releases/medicure-reports-first-quarter-financial-results-for-fiscal-2013) - [Medicure Completes Share Consolidation](https://www.medicure.com/press-releases/medicure-completes-share-consolidation) - [Medicure Announces Agreement to Promote Aggrastat® in the Commonwealth of Puerto Rico](https://www.medicure.com/press-releases/medicure-announces-agreement-to-promote-aggrastat-in-the-commonwealth-of-puerto-rico) - [Medicure Announces Filing of sNDA for AGGRASTAT Label Change](https://www.medicure.com/press-releases/medicure-announces-filing-of-snda-for-aggrastat-label-change) - [Medicure Appoints Brent Fawkes to Board of Directors](https://www.medicure.com/press-releases/medicure-appoints-brent-fawkes-to-board-of-directors) - [Medicure Reports Second Quarter Financial Results for Fiscal 2013](https://www.medicure.com/press-releases/medicure-reports-second-quarter-financial-results-for-fiscal-2013) - [Dr. Albert D. Friesen to File Early Warning Report](https://www.medicure.com/press-releases/dr-albert-d-friesen-to-file-early-warning-report-2) - [Medicure Reports Third Quarter Financial Results for Fiscal 2013](https://www.medicure.com/press-releases/medicure-reports-third-quarter-financial-results-for-fiscal-2013) - [Medicure Announces Grant of Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-options-5) - [Medicure Reports Financial Results for Fiscal 2013](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-fiscal-2013) - [Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT®](https://www.medicure.com/press-releases/medicure-announces-approval-of-recommended-dosing-regimen-for-aggrastat) - [Medicure Reports First Quarter Financial Results for Fiscal 2014](https://www.medicure.com/press-releases/medicure-reports-first-quarter-financial-results-for-fiscal-2014) - [Medicure Reports Second Quarter Financial Results for Fiscal 2014](https://www.medicure.com/press-releases/medicure-reports-second-quarter-financial-results-for-fiscal-2014) - [Medicure Reports Financial Results for the Third Quarter Fiscal 2014](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-the-third-quarter-fiscal-2014) - [Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services](https://www.medicure.com/press-releases/medicure-engages-knight-therapeutics-inc-to-provide-advisory-services) - [Medicure Comments on Recent Trading Activity](https://www.medicure.com/press-releases/medicure-comments-on-recent-trading-activity) - [Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore](https://www.medicure.com/press-releases/medicure-acquires-minority-position-in-pharmaceutical-manufacturer-apicore) - [Medicure Announces Grant of Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-options-4) - [Medicure Announces Shares for Debt Settlement](https://www.medicure.com/press-releases/medicure-announces-shares-for-debt-settlement) - [Medicure Provides Update on Tardoxal and TEND-TD Study](https://www.medicure.com/press-releases/medicure-provides-update-on-tardoxal-and-tend-td-study) - [Medicure Reports Financial Results for Fiscal 2014](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-fiscal-2014) - [Medicure Reports Financial Results for the First Quarter Fiscal 2015](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-the-first-quarter-fiscal-2015) - [Dr. Albert D. Friesen to File Early Warning Report](https://www.medicure.com/press-releases/dr-albert-d-friesen-to-file-early-warning-report) - [Medicure Announces Change in Fiscal Year End and Provides One-Time Guidance on Quarterly Revenue](https://www.medicure.com/press-releases/medicure-announces-change-in-fiscal-year-end-and-provides-one-time-guidance-on-quarterly-revenue) - [Medicure announces issuance of shares under previously announced shares for debt settlement](https://www.medicure.com/press-releases/medicure-announces-issuance-of-shares-under-previously-announced-shares-for-debt-settlement-2) - [Medicure announces shares for debt settlements](https://www.medicure.com/press-releases/medicure-announces-shares-for-debt-settlements) - [Medicure provides quarterly revenue on a calendar basis following change to year end](https://www.medicure.com/press-releases/medicure-provides-quarterly-revenue-on-a-calendar-basis-following-change-to-year-end) - [Medicure announces issuance of shares under previously announced shares for debt settlement](https://www.medicure.com/press-releases/medicure-announces-issuance-of-shares-under-previously-announced-shares-for-debt-settlement) - [Medicure announces grant of options](https://www.medicure.com/press-releases/medicure-announces-grant-of-options-3) - [Medicure reports financial results for the seven months ended December 31, 2014](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-the-seven-months-ended-december-31-2014) - [Medicure to present at the 2015 Bloom Burton & Co. Healthcare Conference](https://www.medicure.com/press-releases/medicure-to-present-at-the-2015-bloom-burton-co-healthcare-conference) - [Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT®](https://www.medicure.com/press-releases/medicure-announces-approval-of-expanded-dosing-time-for-aggrastat) - [Medicure Q1 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q1-results-and-conference-call-dates-2) - [Medicure Reports Financial Results for the First Quarter of 2015](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-the-first-quarter-of-2015) - [Medicure Announces $3.5 Million "Bought Deal" Private Placement](https://www.medicure.com/press-releases/medicure-announces-35-million-bought-deal-private-placement) - [Medicure Closes Bought Deal Private Placement Financing for Gross Proceeds of $4,025,000](https://www.medicure.com/press-releases/medicure-closes-bought-deal-private-placement-financing-for-gross-proceeds-of-4-025-000) - [Medicure Announces Grant Of Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-options-2) - [Medicure Q2 Results And Conference Call Dates](https://www.medicure.com/press-releases/medicure-q2-results-and-conference-call-dates-2) - [Medicure Reports Second Quarter 2015 Financial Results](https://www.medicure.com/press-releases/medicure-reports-second-quarter-2015-financial-results) - [Medicure Announces Filing of sNDA for New AGGRASTAT® Indication](https://www.medicure.com/press-releases/medicure-announces-filing-of-snda-for-new-aggrastat-indication) - [Medicure Q3 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q3-results-and-conference-call-dates-2) - [Medicure Reports Third Quarter 2015 Financial Results](https://www.medicure.com/press-releases/medicure-reports-third-quarter-2015-financial-results) - [Medicure Announces Grant of Stock Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-stock-options-2) - [Medicure Announces PDUFA Action Date for New Aggrastat Indication](https://www.medicure.com/press-releases/medicure-announces-pdufa-action-date-for-new-aggrastat-indication) - [Medicure announces ANDA collaboration with Apicore](https://www.medicure.com/press-releases/medicure-announces-anda-collaboration-with-apicore) - [Medicure Announces Preliminary Revenue For Fiscal 2015](https://www.medicure.com/press-releases/medicure-announces-preliminary-revenue-for-fiscal-2015) - [Medicure to present at Cantech Investment Conference](https://www.medicure.com/press-releases/medicure-to-present-at-cantech-investment-conference) - [Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference](https://www.medicure.com/press-releases/meta-analysis-of-aggrastat-tirofiban-hcl-presented-at-crt-2016-conference) - [Medicure To Announce Fiscal Year 2015 Financial Results on March 30, 2016](https://www.medicure.com/press-releases/medicure-to-announce-fiscal-year-2015-financial-results-on-march-30-2016) - [Medicure Reports Financial Results for Quarter and Year Ended December 31, 2015](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2015) - [Medicure Announces Upcoming Conference Presentations](https://www.medicure.com/press-releases/medicure-announces-upcoming-conference-presentations) - [Medicure Announces Grant of Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-options) - [Medicure to Announce Q1 2016 Financial Results on May 11, 2016](https://www.medicure.com/press-releases/medicure-to-announce-q1-2016-financial-results-on-may-11-2016) - [Medicure Announces Departure of President and Chief Operating Officer](https://www.medicure.com/press-releases/medicure-announces-departure-of-president-and-chief-operating-officer) - [Medicure Files Application for New AGGRASTAT® Product Format](https://www.medicure.com/press-releases/medicure-files-application-for-new-aggrastat-product-format) - [Medicure Reports First Quarter 2016 Financial Results](https://www.medicure.com/press-releases/medicure-reports-first-quarter-2016-financial-results) - [Medicure Receives Response Letter from FDA on AGGRASTAT® sNDA for New Indication](https://www.medicure.com/press-releases/medicure-receives-response-letter-from-fda-on-aggrastat-snda-for-new-indication) - [Medicure to Announce Q2 2016 Financial Results on August 10, 2016](https://www.medicure.com/press-releases/medicure-to-announce-q2-2016-financial-results-on-august-10-2016) - [Medicure Reports Second Quarter 2016 Financial Results](https://www.medicure.com/press-releases/medicure-reports-second-quarter-2016-financial-results) - [FDA Approves New AGGRASTAT® Product Format](https://www.medicure.com/press-releases/fda-approves-new-aggrastat-product-format) - [Medicure to Announce Q3 2016 Financial Results on November 9, 2016](https://www.medicure.com/press-releases/medicure-to-announce-q3-2016-financial-results-on-november-9-2016) - [Medicure Reports Third Quarter 2016 Financial Results](https://www.medicure.com/press-releases/medicure-reports-third-quarter-2016-financial-results) - [Medicure Exercises Option to Acquire Majority Interest in Apicore](https://www.medicure.com/press-releases/medicure-exercises-option-to-acquire-majority-interest-in-apicore) - [Medicure to Hold Investor Call on November 21, 2016](https://www.medicure.com/press-releases/medicure-to-hold-investor-call-on-november-21-2016) - [Medicure Closes Acquisition of Majority Interest in Apicore](https://www.medicure.com/press-releases/medicure-closes-acquisition-of-majority-interest-in-apicore) - [Medicure announces filing of ANDA in collaboration with Apicore](https://www.medicure.com/press-releases/medicure-announces-filing-of-anda-in-collaboration-with-apicore) - [Medicure Provides Apicore Secured Loan to Replace Knight Loan](https://www.medicure.com/press-releases/medicure-provides-apicore-secured-loan-to-replace-knight-loan) - [Medicure Announces FDA Approval for Apicore's Generic Tetrabenazine](https://www.medicure.com/press-releases/medicure-announces-fda-approval-for-apicores-generic-tetrabenazine) - [Medicure to Announce Fiscal Year End 2016 Financial Results on April 26, 2017](https://www.medicure.com/press-releases/medicure-to-announce-fiscal-year-end-2016-financial-results-on-april-26-2017) - [Medicure Reports Financial Results for Quarter and Year Ended December 31, 2016](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2016) - [Medicure Q1 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q1-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended March 31, 2017](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2017) - [Medicure Provides Update on Apicore Purchase Option](https://www.medicure.com/press-releases/medicure-provides-update-on-apicore-purchase-option) - [Medicure Exercises Option to Acquire Additional Interests in Apicore](https://www.medicure.com/press-releases/medicure-exercises-option-to-acquire-additional-interests-in-apicore) - [Medicure Closes Acquisition of Additional Interests in Apicore](https://www.medicure.com/press-releases/medicure-closes-acquisition-of-additional-interests-in-apicore) - [Medicure Q2 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q2-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended June 30, 2017](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2017) - [Medicure Announces Sale of Apicore Business](https://www.medicure.com/press-releases/medicure-announces-sale-of-apicore-business) - [Medicure Acquires Exclusive License to Sell and Market PREXXARTAN® in the U.S. from Carmel Biosciences](https://www.medicure.com/press-releases/medicure-acquires-exclusive-license-to-sell-and-market-prexxartan-in-the-us-from-carmel-biosciences) - [Medicure Q3 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q3-results-and-conference-call-dates) - [Medicure Announces Repayment of Outstanding Debt](https://www.medicure.com/press-releases/medicure-announces-repayment-of-outstanding-debt) - [Medicure Reports Financial Results for Quarter Ended September 30, 2017](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2017) - [Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.](https://www.medicure.com/press-releases/medicure-acquires-exclusive-license-to-sell-and-market-branded-cardiovascular-drug-in-the-us) - [Medicure Announces FDA Approval Received for Prexxartan®](https://www.medicure.com/press-releases/medicure-announces-fda-approval-received-for-prexxartan) - [Medicure Announces Receipt of Deferred Proceeds from Apicore Sale](https://www.medicure.com/press-releases/medicure-announces-receipt-of-deferred-proceeds-from-apicore-sale) - [Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S.](https://www.medicure.com/press-releases/zydus-partners-with-medicure-to-launch-its-nda-product-zypitamag-pitavastatin-in-the-us) - [Medicure Announces an Up-Date on PREXXARTAN® Launch](https://www.medicure.com/press-releases/medicure-announces-an-up-date-on-prexxartan-launch) - [Medicure Announces Further Up-Date on PREXXARTAN®](https://www.medicure.com/press-releases/medicure-announces-further-up-date-on-prexxartan) - [Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018](https://www.medicure.com/press-releases/medicure-to-announce-fiscal-year-end-2017-financial-results-on-april-30-2018) - [Medicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S.](https://www.medicure.com/press-releases/medicure-announces-availability-of-zypitamag-pitavastatin-in-the-us) - [Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2017) - [Medicure Announces Normal Course Issuer Bid](https://www.medicure.com/press-releases/medicure-announces-normal-course-issuer-bid-2) - [Medicure Q1 2018 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q1-2018-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended March 31, 2018](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2018) - [Medicure Q2 2018 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q2-2018-results-and-conference-call-dates) - [Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection](https://www.medicure.com/press-releases/medicure-announces-fda-approval-of-acute-care-cardiovascular-drug-sodium-nitroprusside-injection) - [Medicure Reports Financial Results for Quarter Ended June 30, 2018](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2018) - [Medicure Q3 2018 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q3-2018-results-and-conference-call-dates) - [Medicure Files Patent Infringement Action](https://www.medicure.com/press-releases/medicure-files-patent-infringement-action-2) - [Medicure reports financial results for quarter ended September 30, 2018](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2018) - [Medicure Announces Agreement to Market ReDS™ Device for Congestive Heart Failure Patients in the United States](https://www.medicure.com/press-releases/medicure-announces-agreement-to-market-reds-device-for-congestive-heart-failure-patients-in-the-united-states) - [Medicure Provides Update on Release of Holdback Funds from Apicore Sale](https://www.medicure.com/press-releases/medicure-provides-update-on-release-of-holdback-funds-from-apicore-sale) - [Medicure to Announce Fiscal Year End 2018 Financial Results on April 29, 2019](https://www.medicure.com/press-releases/medicure-to-announce-fiscal-year-end-2018-financial-results-on-april-29-2019) - [Medicure Reports Financial Results for Quarter and Year Ended December 31, 2018](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2018) - [Medicure Appoints Ms. Manon Harvey to its Board of Directors](https://www.medicure.com/press-releases/medicure-appoints-ms-manon-harvey-to-its-board-of-directors) - [Medicure Q1 2019 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q1-2019-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended March 31, 2019](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2019) - [Medicure Announces Renewal of its Normal Course Issuer Bid](https://www.medicure.com/press-releases/medicure-announces-renewal-of-its-normal-course-issuer-bid) - [Medicure Announces Appoinment of Dr. Neil Owens as President and Chief Operating Officer](https://www.medicure.com/press-releases/medicure-announces-appoinment-of-dr-neil-owens-as-president-and-chief-operating-officer) - [Medicure Announces Results of 2019 Annual Meeting of Shareholders](https://www.medicure.com/press-releases/medicure-announces-results-of-2019-annual-meeting-of-shareholders) - [Medicure Q2 2019 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q2-2019-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended June 30, 2019](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2019) - [Medicure Announces Settlement of Patent Infringement Action](https://www.medicure.com/press-releases/medicure-announces-settlement-of-patent-infringement-action-2) - [Medicure Announces Launch of New and Improved ReDS™ PRO](https://www.medicure.com/press-releases/medicure-announces-launch-of-new-and-improved-reds-pro) - [Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™](https://www.medicure.com/press-releases/medicure-announces-acquisition-of-full-united-states-ownership-of-zypitamag) - [Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force](https://www.medicure.com/press-releases/medicure-announces-preferred-pricing-agreement-for-zypitamag-with-the-aids-drug-assistance-program-adap-crisis-task-force) - [Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate](https://www.medicure.com/press-releases/medicure-announces-smile-hf-study-demonstrates-use-of-reds-results-in-58-reduction-in-hospital-readmission-rate) - [Medicure Announces Intention to Commence Substantial Issuer Bid](https://www.medicure.com/press-releases/medicure-announces-intention-to-commence-substantial-issuer-bid) - [Medicure Announces Commencement of Substantial Issuer Bid](https://www.medicure.com/press-releases/medicure-announces-commencement-of-substantial-issuer-bid) - [Medicure Q3 2019 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q3-2019-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended September 30, 2019](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2019) - [Medicure Announces Settlement of Holdback Dispute from Apicore Sale](https://www.medicure.com/press-releases/medicure-announces-settlement-of-holdback-dispute-from-apicore-sale) - [Medicure Files Patent Infringement Action](https://www.medicure.com/press-releases/medicure-files-patent-infringement-action) - [Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)](https://www.medicure.com/press-releases/medicure-announces-completion-of-enrollment-for-fabolus-faster-phase-4-clinical-trial-of-aggrastat-tirofiban-hydrochloride-injection-vs-kengreal-cangrelor-in-patients-undergoing-percutaneous-coronary-intervention-pci) - [Medicure Announces Preliminary Results of Substantial Issuer Bid](https://www.medicure.com/press-releases/medicure-announces-preliminary-results-of-substantial-issuer-bid) - [Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study](https://www.medicure.com/press-releases/medicure-announces-the-completion-of-shortened-aggrastat-versus-integrilin-in-percutaneous-coronary-intervention-savi-pci-study) - [Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020](https://www.medicure.com/press-releases/medicure-to-announce-fiscal-year-end-2019-financial-results-on-april-15-2020) - [Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2019) - [Medicure Q1 2020 results and conference call dates](https://www.medicure.com/press-releases/medicure-q1-2020-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended March 31, 2020](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2020) - [Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020](https://www.medicure.com/press-releases/medicure-announces-top-line-data-from-fabolus-faster-trial-with-aggrastat-will-be-presented-at-the-pcr-e-course-late-breaking-trial-sessions-june-27-2020) - [Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG™ (Pitavastatin) Tablets](https://www.medicure.com/press-releases/medicure-announces-a-direct-to-patient-online-pharmacy-program-for-distribution-of-zypitamag-pitavastatin-tablets) - [Medicure Announces Normal Course Issuer Bid](https://www.medicure.com/press-releases/medicure-announces-normal-course-issuer-bid) - [Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation](https://www.medicure.com/press-releases/medicure-announces-positive-results-for-aggrastat-in-the-fabolus-faster-trial-and-publication-in-the-journal-circulation) - [Medicure Q2 2020 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q2-2020-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended June 30, 2020](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2020) - [Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement](https://www.medicure.com/press-releases/medicure-announces-termination-of-redstm-pro-marketing-and-distribution-agreement) - [Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports](https://www.medicure.com/press-releases/medicure-announces-aggrastat-shows-promise-in-treating-thrombotic-complications-due-to-covid-19-in-early-clinical-reports) - [Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar](https://www.medicure.com/press-releases/medicure-announces-an-agreement-with-reliance-life-sciences-for-the-marketing-rights-of-a-cardiovascular-biosimilar) - [Medicure Q3 2020 Results and Conference Call Dates](https://www.medicure.com/press-releases/medicure-q3-2020-results-and-conference-call-dates) - [Medicure Reports Financial Results for Quarter Ended September 30, 2020](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2020) - [Medicure Announces Settlement of Patent Infringement Action](https://www.medicure.com/press-releases/medicure-announces-settlement-of-patent-infringement-action) - [Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.](https://www.medicure.com/press-releases/medicure-retains-investor-relations-firm-renmark-financial-communications-inc) - [Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug](https://www.medicure.com/press-releases/medicure-enters-the-us-online-pharmacy-world-with-acquisition-of-marley-drug) - [Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency](https://www.medicure.com/press-releases/medicure-announces-pivotal-phase-3-trial-ind-filing-with-fda-for-treatment-of-seizures-associated-with-pyridox-am-ine-5-phosphate-oxidase-pnpo-deficiency) - [Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Managem](https://www.medicure.com/press-releases/medicure-announces-early-completion-of-enrollment-for-ispasm-a-phase-1-2a-exploratory-clinical-trial-of-aggrastat-tirofiban-hydrochloride-injection-vs-placebo-for-induced-suppression-of-platelets-activity-in-aneurysmal-subarachnoid-hemorrhage-managem) - [Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021](https://www.medicure.com/press-releases/medicure-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-monday-february-8-2021) - [Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, February 23, 2021](https://www.medicure.com/press-releases/medicure-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-tuesday-february-23-2021) - [Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 9, 2021](https://www.medicure.com/press-releases/medicure-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-tuesday-march-9-2021) - [Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021](https://www.medicure.com/press-releases/medicure-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-tuesday-march-30-2021) - [Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2020) - [Medicure Announces Resignation of Chief Financial Officer and Succession Plan](https://www.medicure.com/press-releases/medicure-announces-resignation-of-chief-financial-officer-and-succession-plan-2) - [Medicure 2020 Annual and Q1 2021 Results and Conference Call Date](https://www.medicure.com/press-releases/medicure-2020-annual-and-q1-2021-results-and-conference-call-date) - [Medicure Reports Financial Results for Quarter Ended March 31, 2021](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2021) - [Medicure Announces Appointment of David Gurvey as Chief Financial Officer](https://www.medicure.com/press-releases/medicure-announces-appointment-of-david-gurvey-as-chief-financial-officer) - [Medicure Announces Grant of Stock Options](https://www.medicure.com/press-releases/medicure-announces-grant-of-stock-options) - [Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-the-second-quarter-ended-june-30-2021) - [Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint](https://www.medicure.com/press-releases/medicure-announces-that-the-shortened-aggrastat-versus-integrilin-in-percutaneous-coronary-intervention-savi-pci-study-has-met-its-primary-endpoint) - [Medicure Reports Financial Results for Quarter Ended September 30, 2021](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2021) - [Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans](https://www.medicure.com/press-releases/medicure-plans-to-launch-innovative-e-commerce-pharmacy-platform-offering-hundreds-of-medications-directly-to-millions-of-americans) - [Medicure Launches E-Commerce Pharmacy Platform - marleydrug.com Through its Subsidiary Marley Drug Pharmacy](https://www.medicure.com/press-releases/medicure-launches-e-commerce-pharmacy-platform-marleydrugcom-through-its-subsidiary-marley-drug-pharmacy) - [Medicure's Subsidiary - Marley Drug to Partner with RxSpark, the Next Generation in Pharmacy Discount Programs, to be its Sole Mail-Order Pharmacy](https://www.medicure.com/press-releases/medicures-subsidiary-marley-drug-to-partner-with-rxspark-the-next-generation-in-pharmacy-discount-programs-to-be-its-sole-mail-order-pharmacy) - [MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN](https://www.medicure.com/press-releases/medicure-announces-resignation-of-chief-financial-officer-and-succession-plan) - [MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST](https://www.medicure.com/press-releases/medicure-to-report-financial-results-for-year-ended-december-31-2021-on-april-28th-at-7-30-am-cst) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2021) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2022-and-appointment-of-haaris-uddin-as-chief-financial-officer) - [MEDICURE ANNOUNCES RESULTS OF 2022 AGM](https://www.medicure.com/press-releases/medicure-announces-results-of-2022-agm) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-august-25-2022-call-at-8-30-am-et-for-quarter-ended-june-30-2022) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2022) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-november-25-2022-call-at-8-30-am-et-for-quarter-ended-september-30-2022) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2022) - [MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS](https://www.medicure.com/press-releases/medicure-announces-resignation-of-board-member-and-grant-of-stock-options) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 10, 2023 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2022](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-april-10-2023-call-at-8-30-am-et-for-quarter-and-year-ended-december-31-2022) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2022](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2022) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2023](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2023) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON JULY 31, 2023 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2023](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-july-31-2023-call-at-8-30-am-et-for-quarter-ended-june-30-2023) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2023](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2023) - [MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN (ZYPITAMAG) TO PEOPLE LIVING WITH HIV](https://www.medicure.com/press-releases/medicure-reiterates-its-commitment-to-providing-exceptional-access-to-its-branded-pitavastatin-zypitamag-to-people-living-with-hiv) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2023](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2023) - [MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE](https://www.medicure.com/press-releases/medicure-announces-fda-provides-complete-approval-to-enroll-patients-in-its-pivotal-phase-3-trial-for-treatment-of-rare-pediatric-disease) - [MEDICURE ANNOUNCES NEW PARTNERSHIP THROUGH ITS MARLEY DRUG SUBSIDIARY TO PROVIDE BRENZAVVY® AS AN AFFORDABLE MEDICATION FOR AMERICANS WITH TYPE 2 DIABETES](https://www.medicure.com/press-releases/medicure-announces-new-partnership-through-its-marley-drug-subsidiary-to-provide-brenzavvy-as-an-affordable-medication-for-americans-with-type-2-diabetes) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 9, 2024 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-april-9-2024-call-at-8-30-am-et-for-quarter-and-year-ended-december-31-2023) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2023) - [MEDICURE RECEIVES US FDA FAST TRACK DESIGNATION FOR MC-1 FOR PNPO DEFICIENCY](https://www.medicure.com/press-releases/medicure-receives-us-fda-fast-track-designation-for-mc-1-for-pnpo-deficiency) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2024 AND ANNUAL GENERAL MEETING DIRECTOR ELECTION RESULTS](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2024-and-annual-general-meeting-director-election-results) - [MEDICURE ANNOUNCES SIGNING OF ASSET PURCHASE AGREEMENT WITH CANAM BIORESEARCH INC. FOR ACQUISITION OF INTELLECTUAL PROPERTY](https://www.medicure.com/press-releases/medicure-announces-signing-of-asset-purchase-agreement-with-canam-bioresearch-inc-for-acquisition-of-intellectual-property) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2024](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2024) - [MEDICURE ANNOUNCES CLOSING OF ASSET PURCHASE AGREEMENT WITH CANAM BIORESEARCH FOR ACQUISITION OF INTELLECTUAL PROPERTY](https://www.medicure.com/press-releases/medicure-announces-closing-of-asset-purchase-agreement-with-canam-bioresearch-for-acquisition-of-intellectual-property) - [MEDICURE ANNOUNCES POSITIVE SETTLEMENT OF PRODUCT DEVELOPMENT AND SUPPLY CONTRACTS](https://www.medicure.com/press-releases/medicure-announces-positive-settlement-of-product-development-and-supply-contracts) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 26, 2024 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2024 AND ANNOUNCES RESIGNATION OF BOARD MEMBER](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-november-26-2024-call-at-8-30-am-et-for-quarter-ended-september-30-2024-and-announces-resignation-of-board-member) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2024](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2024) - [MEDICURE ANNOUNCES EXPANSION OF ITS PHARMACY BUSINESS THROUGH SIGNING OF A PURCHASE AGREEMENT FOR THE ACQUISITION OF GATEWAY MEDICAL PHARMACY](https://www.medicure.com/press-releases/medicure-announces-expansion-of-its-pharmacy-business-through-signing-of-a-purchase-agreement-for-the-acquisition-of-gateway-medical-pharmacy) - [MEDICURE ANNOUNCES CLOSING OF PURCHASE AGREEMENT FOR THE ACQUISITION OF GATEWAY MEDICAL PHARMACY](https://www.medicure.com/press-releases/medicure-announces-closing-of-purchase-agreement-for-the-acquisition-of-gateway-medical-pharmacy) - [MEDICURE ANNOUNCES FURTHER EXPANSION OF ITS PHARMACY BUSINESS THROUGH SIGNING OF A PURCHASE AGREEMENT FOR THE ACQUISITION OF WEST OLYMPIA PHARMACY](https://www.medicure.com/press-releases/medicure-announces-further-expansion-of-its-pharmacy-business-through-signing-of-a-purchase-agreement-for-the-acquisition-of-west-olympia-pharmacy) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 29, 2025 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2024](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-april-29-2025-call-at-8-30-am-et-for-quarter-and-year-ended-december-31-2024) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2024](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-and-year-ended-december-31-2024) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2025 AND ANNUAL GENERAL MEETING DIRECTOR ELECTION RESULTS](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2025-and-annual-general-meeting-director-election-results) - [MEDICURE ANNOUNCES CLOSING OF PURCHASE AGREEMENT FOR THE ACQUISITION OF WEST OLYMPIA PHARMACY](https://www.medicure.com/press-releases/medicure-announces-closing-of-purchase-agreement-for-the-acquisition-of-west-olympia-pharmacy) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 21, 2025 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2025](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-august-21-2025-call-at-8-30-am-et-for-quarter-ended-june-30-2025) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2025](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-june-30-2025) - [MEDICURE ANNOUNCES UPDATE ON ENROLLMENT IN ITS MEND-PNPO PHASE 3 CLINICAL TRIAL AND PRESENTATION OF THE TRIAL DESIGN AND BASELINE DATA AT THE 2025 CHILD NEUROLOGY SOCIETY CONFERENCE](https://www.medicure.com/press-releases/medicure-announces-update-on-enrollment-in-its-mend-pnpo-phase-3-clinical-trial-and-presentation-of-the-trial-design-and-baseline-data-at-the-2025-child-neurology-society-conference) - [MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 20, 2025 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2025](https://www.medicure.com/press-releases/medicure-to-present-financial-results-on-november-20-2025-call-at-8-30-am-et-for-quarter-ended-september-30-2025) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2025](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-september-30-2025) - [MEDICURE ANNOUNCES RESIGNATION OF PRESIDENT AND CHIEF OPERATING OFFICER](https://www.medicure.com/press-releases/medicure-announces-resignation-of-president-and-chief-operating-officer) - [MEDICURE REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 AND SCHEDULES APRIL 27, 2026 CONFERENCE CALL](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-the-year-ended-december-31-2025-and-schedules-april-27-2026-conference-call) - [MEDICURE ANNOUNCES AGM RESULTS AND APPOINTMENT OF NEW DIRECTOR](https://www.medicure.com/press-releases/medicure-announces-agm-results-and-appointment-of-new-director) - [MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2026 AND SCHEDULES MAY 25, 2026 CONFERENCE CALL](https://www.medicure.com/press-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2026-and-schedules-may-25-2026-conference-call) - [MEDICURE ANNOUNCES CFO CHANGE](https://www.medicure.com/press-releases/medicure-announces-cfo-change)